Dalteparin sodium + Dalteparin sodium/aspirin
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thromboembolism
Conditions
Venous Thromboembolism
Trial Timeline
Mar 1, 2010 → Dec 1, 2011
NCT ID
NCT01050153About Dalteparin sodium + Dalteparin sodium/aspirin
Dalteparin sodium + Dalteparin sodium/aspirin is a pre-clinical stage product being developed by Eisai for Venous Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT01050153. Target conditions include Venous Thromboembolism.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01050153 | Pre-clinical | Completed |
Competing Products
20 competing products in Venous Thromboembolism